全文获取类型
| 收费全文 | 91594篇 |
| 免费 | 8274篇 |
| 国内免费 | 2352篇 |
专业分类
| 耳鼻咽喉 | 844篇 |
| 儿科学 | 1657篇 |
| 妇产科学 | 1046篇 |
| 基础医学 | 6891篇 |
| 口腔科学 | 1059篇 |
| 临床医学 | 12971篇 |
| 内科学 | 18124篇 |
| 皮肤病学 | 672篇 |
| 神经病学 | 4290篇 |
| 特种医学 | 1809篇 |
| 外国民族医学 | 7篇 |
| 外科学 | 7240篇 |
| 综合类 | 16851篇 |
| 现状与发展 | 11篇 |
| 一般理论 | 1篇 |
| 预防医学 | 8865篇 |
| 眼科学 | 1219篇 |
| 药学 | 10197篇 |
| 133篇 | |
| 中国医学 | 5373篇 |
| 肿瘤学 | 2960篇 |
出版年
| 2024年 | 113篇 |
| 2023年 | 1622篇 |
| 2022年 | 2140篇 |
| 2021年 | 3660篇 |
| 2020年 | 3873篇 |
| 2019年 | 3677篇 |
| 2018年 | 4374篇 |
| 2017年 | 3189篇 |
| 2016年 | 3540篇 |
| 2015年 | 3316篇 |
| 2014年 | 7202篇 |
| 2013年 | 7902篇 |
| 2012年 | 6042篇 |
| 2011年 | 6060篇 |
| 2010年 | 4773篇 |
| 2009年 | 4159篇 |
| 2008年 | 3846篇 |
| 2007年 | 3941篇 |
| 2006年 | 3358篇 |
| 2005年 | 3068篇 |
| 2004年 | 2515篇 |
| 2003年 | 2299篇 |
| 2002年 | 1781篇 |
| 2001年 | 1697篇 |
| 2000年 | 1607篇 |
| 1999年 | 1384篇 |
| 1998年 | 1182篇 |
| 1997年 | 1044篇 |
| 1996年 | 923篇 |
| 1995年 | 926篇 |
| 1994年 | 873篇 |
| 1993年 | 683篇 |
| 1992年 | 731篇 |
| 1991年 | 473篇 |
| 1990年 | 549篇 |
| 1989年 | 367篇 |
| 1988年 | 433篇 |
| 1987年 | 362篇 |
| 1986年 | 304篇 |
| 1985年 | 418篇 |
| 1984年 | 380篇 |
| 1983年 | 204篇 |
| 1982年 | 270篇 |
| 1981年 | 198篇 |
| 1980年 | 218篇 |
| 1979年 | 103篇 |
| 1978年 | 98篇 |
| 1977年 | 88篇 |
| 1976年 | 81篇 |
| 1974年 | 51篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
91.
92.
93.
目的探讨自血穴位注射疗法联合马来酸茚达特罗治疗老年稳定期慢性阻塞性肺疾病(COPD)的临床疗效及其对患者炎性因子、免疫功能及肺功能的影响。 方法将2015年5月至2016年5月我院收治的86例老年缓解期COPD患者分为观察组与对照组。对照组给予马来酸茚达特罗治疗，观察组在对照组治疗基础上另给予自血穴位注射疗法。治疗12周后，评价2组临床疗效。治疗前及治疗12周后，分别检测2组患者肺功能指标(FEV1、FVC与PEF)，炎性因子(IL-8、α1-AT、IL-6及TNF-α)，免疫功能指标(IgG、IgA、CD3＋及CD4＋)水平。治疗期间，对2组患者的不良反应进行密切观察。 结果治疗后二组患者各项检测指标均优于治疗前。治疗12周后，观察组总有效率为90.7%，明显高于对照组的72.1%(P<0.05)。治疗12周后，观察组FEV1、FVC与PEF等肺功能指标，IgG、IgA、CD3＋及CD4＋等免疫功能指标水平均明显高于对照组(P<0.05)，而IL-8、α1-AT、IL-6及TNF-α含量分别为(23.23±3.87)ng/L、(3.43±0.41)g/L、(52.25±5.38)ng/L及(43.12±3.98)ng/L，改善程度均明显优于对照组(P<0.05)。治疗期间，2组患者均未出现严重不良反应。 结论自血穴位注射疗法联合马来酸茚达特罗治疗老年稳定期COPD疗效确切，可有效改善患者炎症水平，值得进行深入研究。 相似文献
94.
95.
96.
Pedro Lopez Matheus Daros Pinto Ronei Silveira Pinto 《Ultrasound in medicine & biology》2019,45(2):612-616
In the work described here, our aim was to determine, in an elderly population, changes in muscle thickness (MT), cross-sectional area (CSA) and echo intensity (EI) of the quadriceps muscles at four time points (0, 5, 10 and 15 min; i.e., T0, T5, T10 and T15, respectively) after changing from a standing to supine position. Twenty-one elderly participants (14 men: 68.1 ± 4.6 y; 8 women: 66.8 ± 4.1 y) were evaluated at four time points. Rectus femoris CSA (RFCSA), MT and EI of the quadriceps femoris (QF) muscles were assessed. EI significantly increased from T0 to T5, T10 and T15 (p < 0.001), whereas no differences were observed between T5 and T15 in the rectus femoris (RFEI), vastus intermedius (VIEI) and quadriceps femoris (QFEI). No differences were observed between any time points in the RFCSA and MT of QF muscles. In summary, these results suggest that periods >5 min are not necessary to obtain consistent MT and EI measurements of quadriceps femoris muscles in the elderly population. 相似文献
97.
Javed Butler Mei Yang Massimiliano Alfonzo Manzi Gregory P. Hess Mahesh J. Patel Thomas Rhodes Michael M. Givertz 《Journal of the American College of Cardiology》2019,73(8):935-944
Background
Epidemiology of patients with worsening heart failure and reduced ejection fraction (HFrEF) in the real-world setting is not well described.Objectives
The purpose of this study was to describe incidence, clinical characteristics, treatment, and outcomes of patients with HFrEF who develop worsening heart failure (HF) in the real-world setting.Methods
Data on patients with incident HFrEF from the National Cardiovascular Data Registry PINNACLE were linked to pharmacy, private practitioner, and hospital claims databases. Incidence, clinical characteristics, treatment (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist) and outcomes of patients with worsening HF, defined as ≥90 days of stable HF with subsequent worsening requiring intravenous diuretic agents, were assessed.Results
Of 11,064 HFrEF patients, 1,851 (17%) developed worsening HF on average 1.5 years following initial HF diagnosis. Patients who developed worsening HF were more likely to be African American, be octogenarians, and have higher comorbidity burden (p < 0.001). At the onset of worsening HF, 42.4% of patients were on monotherapy, 43.4% were on dual therapy, and 14.1% were on triple therapy. A total of 48%, 61%, and 98% of patients were on >50% target dose for angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta-blocker, and mineralocorticoid receptor antagonist, respectively. The 2-year mortality rate was 22.5%, and 56% of patients were rehospitalized within 30 days of the worsening HF event.Conclusions
In the real-world setting, 1 in 6 patients with HFrEF develop worsening HF within 18 months of HF diagnosis. These patients have a high risk for 2-year mortality and recurrent HF hospitalizations. The use of standard-of-care therapies both before and after the onset of worsening HF is low. With high unmet medical need, patients with worsening HF require novel treatment strategies as well as greater optimization of existing guideline-directed therapy. 相似文献98.
99.
100.